Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | KIF5B | P33176 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099339 | 1.00 | KDR (0.58) | KDRCSF1RPDGFRABRAFRET | |
| SCHEMBL7104227 | 0.86 | KDR (0.56) | KDRCSF1RPDGFRABRAFRET | |
| SCHEMBL1100627 | 0.83 | KDR (0.51) | KDRCSF1RPDGFRABRAFKIT | |
| SCHEMBL1098153 | 0.83 | KDR (0.51) | KDRCSF1RPDGFRABRAFKIT | |
| SCHEMBL1098715 | 0.78 | KDR (0.52) | KDRCSF1RPDGFRABRAFRET | |
| SCHEMBL1099345 | 0.78 | KDR (0.52) | KDRCSF1RPDGFRABRAFRET | |
| SCHEMBL844432 | 0.75 | ATM (0.56) | — | |
| SCHEMBL3217896 | 0.75 | ATM (0.56) | — | |
| SCHEMBL844431 | 0.75 | ATM (0.56) | — | |
| SCHEMBL3812435 | 0.74 | KDM4E (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | KDR 27/4885CSF1R 362/4885PDGFRA 368/4885 |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | AQP1, F12, AQP3 | KDR 34/4885CSF1R 357/4885PDGFRA 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.